Dr Reddy’s unveils rivastigmine tartrate capsules

23 Sep 2011 Evaluate

Dr Reddy’s Laboratories has launched rivastigmine tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of Exelon capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (USFDA) of the company’s Abbreviated New Drug Application (ANDA) for rivastigmine tartrate capsules.

The Exelon brand and generic rivastigmine tartrate had US sales of about $92.6 million for the most recent twelve months ending June 2011. Dr Reddy’s rivastigmine tartrate capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg strengths are available in 60 count bottles.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1194.55 -19.40 (-1.60%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.